Oncology

GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.

Researchers at Brown University may provide a new early diagnostic test for pancreatic cancer.

Encouraging results from mid-trial analysis have prompted an early halt of the clinical trial for palbociclib and plans to apply for approval.

Orteronel combined with prednisone showed significant PFS but not OS in a double-blind, randomized phase 3 trial.

A leading Belgium-based company that offers personalized medicine to cancer patients, OncoDNA, has chosen to partner with N-of-One for interpretation of next-generation sequencing data of tumor samples.

BMS announced in a press release the breakthrough designation received by it's PD-1 inhibitor antibody, nivolumab, for treating Hodgkin's lymphoma.

LETTER TO THE EDITOR.

Stage IV NSCLC patients with metastatic SCC showed significantly improved survival when necitumumab, an EGFR-targeted antibody, was combined with gemcitabine and cisplatin (11.5 months), compared to chemotherapy alone (9.9 months).

Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates